A secondary endpoint in the trial is decrease of peripheral inflammatory markers as defined by a composite cytokine score derived from measurements of TNF-α, IL-6, CRP, and IP-10, and which is significantly increased in participants with DS in the HTP study (Figure 6d). Here, TNF is linked to Dravet syndrome.